Three routes, three prices, one page
The weight-loss page prices a weekly semaglutide injection, a weekly tirzepatide injection and a daily oral semaglutide, each with a single figure. Pricing the oral route in the open is uncommon here, and pricing it above the injection rather than below is a useful signal about what it costs to supply.
The page states the figure includes consultation, medication and shipping. That makes it a bill rather than a line item, which is what a comparison needs.
The commitment question the page does not settle
Every rate is labelled as applying on the twelve-month plan. The same page says there are no long-term contracts and that a patient can pause or cancel from a dashboard in one click with no calls and no fees. Those two things can both be true only if the plan length is a pricing tier rather than a contract, and the page never says so.
This review does not resolve it. The plan label is carried in each price qualifier so it travels with the number wherever the figure appears, and the contradiction is recorded as a finding. A reader who intends to try one month should ask which rate applies to them before enrolling, because the advertised one is not described as a month-to-month rate.
The price holds through titration
Nolu states that the price is the same at every dose. That removes the failure mode where the bill climbs at exactly the point the medication starts working, and it is the reason a flat-rate seller is usually easier to plan around than a laddered one.
It also states there are no membership fees, which is a claim about the whole bill rather than about one line of it, and repeats it in the frequently asked questions rather than confining it to a footnote.
Coverage, with a caveat attached to itself
The footer states the service runs in all fifty states plus the District of Columbia, and then says some services may not be available in all fifty states or the District of Columbia. The claim carries its own qualification.
Beyond that, the compounding pharmacies are described as state-licensed and never named, no prescribing clinician or medical director is identified, and the site states plainly that compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness or quality.
Nolu's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $149/moper month on the twelve-month plan; the same page states the price includes consultation, medication and shipping and that a patient can cancel at any time | September 2026source |
| Tirzepatide (compounded) | $229/moper month on the twelve-month plan; the same page states the price includes consultation, medication and shipping and that a patient can cancel at any time | September 2026source |
| Semaglutide (compounded-oral) | $159/moper month on the twelve-month plan for the daily oral formulation, which the page prices above the weekly injection | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See Nolu's current price →Good fit if
- Readers who want a daily oral GLP-1 priced beside the weekly injections rather than hidden behind an enquiry.
- Patients who want one figure that does not move as the dose climbs.
- Anyone who wants consultation, medication and shipping stated as covered and membership stated as absent.
- Readers in smaller markets, given the stated fifty-state-plus-DC footprint.
Look elsewhere if
- Anyone intending to try a single month, since every advertised rate is labelled a twelve-month plan rate.
- Readers who need the compounding pharmacy named.
- Patients who want a named prescribing clinician or medical director.
- Anyone who wants a brand-name, FDA-approved GLP-1.
How this review was verified
- Read the weight-loss page at its source URL and logged all three figures with the date they were read.
- Carried the twelve-month plan label into each price qualifier so the commitment travels with the number.
- Recorded the contradiction between the plan label and the no-long-term-contracts language as a finding rather than choosing between them.
- Recorded the state footprint as stated, together with the caveat the same footer attaches to it.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter for the brand or the operating company.